NASDAQ:ROIV Roivant Sciences Q2 2027 Earnings Date & Estimates $35.16 -0.28 (-0.78%) As of 10:23 AM Eastern This is a fair market value price provided by Massive. Learn more. Roivant Sciences is scheduled to report Q2 2027 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ2 2027Announcement DateNovember 9, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Roivant Sciences in Q2 2027Roivant Sciences is expected to post earnings of -$0.41 per share on revenue of $3.74 million. Roivant Sciences last reported on August 7, 2026, posting -$0.26 per share and beating the -$0.2996 consensus estimate. Roivant Sciences has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.41Expected Revenue$3.74 millionRecent Track RecordLast ReportedQ1 2027Last Quarter EPS-$0.26 (Beat by +$0.0396)Last Quarter Revenue$1.44 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q2 2027 CallEarnings HistoryCompany ProfileQ1 2027 Earnings ReportQ4 Earnings ReportQ3 2025 Earnings Report Roivant Sciences Q2 2027 Earnings FAQ When does Roivant Sciences report Q2 2027 earnings? Roivant Sciences (NASDAQ:ROIV) is scheduled to report Q2 2027 earnings on Monday, November 9, 2026, before market opens. What time is Roivant Sciences' Q2 2027 earnings call? Roivant Sciences' Q2 2027 earnings conference call is scheduled for Monday, November 9, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Roivant Sciences? Analysts expect Roivant Sciences to post earnings of -$0.41 per share for Q2 2027. How much revenue is Roivant Sciences expected to report? The consensus revenue estimate for Roivant Sciences is $3.74 million for Q2 2027. Roivant Sciences Earnings HeadlinesRoivant Sciences Ltd. (NASDAQ:ROIV) Stock Has Consensus Target Price of $45.64October 7, 2026 | americanbankingnews.comComparing Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)October 6, 2026 | americanbankingnews.comFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.October 12 at 1:00 AM | Monetary Gold (Ad)Roivant's Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV)October 5, 2026 | americanbankingnews.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Company StockOctober 3, 2026 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)September 27, 2026 | theglobeandmail.comSee More Roivant Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Roivant Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Roivant Sciences and other key companies, straight to your email. Email Address About Roivant SciencesRoivant Sciences (NASDAQ:ROIV) (NASDAQ:ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with serious or underserved diseases. The company operates through a network of subsidiary companies, known as “Vants,” each dedicated to specific therapeutic areas, drug candidates or commercial opportunities. Roivant’s research and development activities have included treatments for immune-mediated diseases, rare disorders, oncology and conditions affecting the nervous system. Its portfolio has included investigational therapies such as batoclimab, an antibody being studied in several autoimmune conditions, and brepocitinib, an immunomodulatory therapy evaluated for inflammatory and autoimmune diseases. The company has also pursued strategic partnerships, acquisitions and licensing transactions to advance or commercialize drug candidates. Founded in 2014, Roivant is headquartered in Basel, Switzerland, and maintains operations in the United States and other international markets. Matt Gline has served as the company’s chief executive officer since 2021. Roivant has historically used subsidiary companies and collaborations with larger pharmaceutical businesses to develop medicines and expand their potential commercial reach.View Roivant Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsC.H. Robinson Bets Its AI Story on RXO—But the Market Isn't SoldApplied Digital’s Hidden Moat Could Unlock Massive Upside Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
